Rox Medical raises $40M to advance hypertension device

Rox Medical Coupler--Courtesy of Rox Medical

Rox Medical pulled in $40 million in Series E financing, with plans to launch a U.S. pivotal trial for its mechanical solution for uncontrolled hypertension.

The Rox Medical Coupler is a stent-like device that mechanically lowers blood pressure by connecting the artery and vein in the upper leg, according to the company. It is implanted between the femoral vein and femoral artery during an hour-long, minimally invasive outpatient procedure. This mechanical approach sets it apart from other hypertension devices that work by targeting the sympathetic nervous system.

Therapies such as Medtronic’s renal denervation system selectively disable nerves within the sympathetic nervous system in order to lower the electrical stimulation of other parts of the SNS, including the heart and blood vessels. But these may only work in younger patients and can take a long time to produce effects, Rox Medical said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Apple Tree Partners and Novartis Venture Fund led the round. Existing investors Versant Ventures and Domain Associates also participated.

"ROX has the potential to solve many challenges with their revolutionary device by providing instantaneous and predictable outcomes for patients and physicians. The company is now well-positioned for success in this late clinical phase of development,” said David McIntyre, partner at Apple Tree Partners, in the statement.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.